Avid Bioservices Inc (CDMO)

[north40000]

https://seekingalpha.com/article/4114530-fda-approval-gilead-car-t-therapy-will-move-needle

See earlier comments here earlier today of Sunstar, as well as MSKCC:

"There are a few risks associated with the approval of Yescarta. The first risk that must be pointed out, is that CAR-T therapies have a lot of safety risks. More than 43% of patients taking Yescarta had anemia and low amounts of white blood cells. Two patients on Yescarta died due to treatment related complications. In addition, both Yescarta and Kymriah[NVS] will have a boxed warning about cytokine release syndrome. Cytokine release syndrome (also called cytokine storms) is a reaction patients pertain to CAR-T therapy. In essence it causes a never ending loop between cytokines and white blood cells that is highly dangerous. There are times when this can be dealt with by giving patients immunosupressant drugs. If immunosupressant drugs are unsuccessful, then cytokine release syndrome becomes fatal. With the large price tag, and many safety risks it's too early to tell how well Yescarta will sell when it launches in the market. On the other hand, most of these patients don't respond to two or more systemic therapies. Therefore, having a third option after failing other therapies is highly welcomed."